Targeting inflammation and cartilage breakdown in two main cellular actors of the diseased joint, and alleviating pain in vivo, confers to liraglutide the properties of a potential disease modifier, which could constitute a new treatment for OA
These effects are typically most pronounced when starting treatment or increasing the dose, and they are usually mild to moderate in severity and transient
All books, conference papers, theses, editorials, review articles, meta-analyses, in-vitro studies, laboratory studies, and animal studies were excluded
Finally, the lawyer for Eli Lilly requested an early motion for summary judgment date
Patients electing for UCWM only served as a control group matched for age-, sex- and BMI (1:2 ratio)
Cell Metab 31(1):92104.e5